The global cosmetics safety assessment market is estimated at USD 3.1B in 2025, driven by accelerating MoCRA enforcement timelines and expanding EU Cosmetics Regulation compliance audits. MoCRA's mandatory facility registration and adverse-event reporting requirements represent the single largest near-term demand catal The cosmetics safety assessment market sits at the intersection of regulatory compliance, ingredient science, and expanding consumer-facing clean beauty claims.
Market Size (2025)
USD 3.1 Billion
Projected (2033)
USD 4.8 Billion
CAGR
5.6%
Published
May 2026
Select User License
Selected
PDF Report
USD 4,900
USD 3,200
The Cosmetics Safety Assessment Market is valued at USD 3.1 Billion and is projected to grow at a CAGR of 5.6% during 2026 - 2033. Europe holds the largest regional share, while Asia Pacific is the fastest-growing market.
Study Period
2019 - 2033
Market Size (2025)
USD 3.1 Billion
CAGR (2026 - 2033)
5.6%
Largest Market
Europe
Fastest Growing
Asia Pacific
Market Concentration
Medium
*Disclaimer: Major Players sorted in no particular order
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Global Cosmetics Safety Assessment market valued at USD 3.1 Billion in 2025, projected to reach USD 4.8 Billion by 2033 at 5.6% CAGR
Key growth driver: MoCRA Enforcement Ramp (United States) (High, +9% CAGR impact)
Europe holds the largest market share, while Asia Pacific is the fastest-growing region
AI Impact: AI's most immediate impact on cosmetics safety assessment is the compression of preliminary hazard screening timelines. QSAR modeling platforms (Lhasa Nexus, OECD QSAR Toolbox, Derek Nexus) and automated read-across engines can assess structural analogy between a new cosmetic ingredient and a database of tested compounds, generating probabilistic hazard flags in hours versus weeks for a full in vitro battery.
15 leading companies profiled including Eurofins Scientific SE, SGS SA, Intertek Group plc and 12 more
AI's most immediate impact on cosmetics safety assessment is the compression of preliminary hazard screening timelines. QSAR modeling platforms (Lhasa Nexus, OECD QSAR Toolbox, Derek Nexus) and automated read-across engines can assess structural analogy between a new cosmetic ingredient and a database of tested compounds, generating probabilistic hazard flags in hours versus weeks for a full in vitro battery. For a brand formulator evaluating 50 candidate ingredients for a clean-label reformulation, this represents a material reduction in pre-testing spend. The commercial implication for testing labs is bifurcated: entry-level physicochemical hazard screening faces structural price compression, while validated in vitro assays (which regulators still require as confirmatory evidence) and clinical studies are insulated. AI is shifting the testing spend mix toward higher-value endpoints, which is net-positive for specialist labs with clinical capability and net-negative for high-volume, low-complexity generalists.
AI demand forecasting tools applied to brand inventory management have a secondary effect on cosmetics safety assessment: more accurate sell-through prediction reduces the incidence of extended shelf-life products that would otherwise trigger stability re-testing mandates. Brands using AI-powered demand forecasting (e.g., integrated into retail media dashboards via Amazon Vendor Central analytics or Sephora's supply chain JBP tooling) are reporting reduced SKU obsolescence, which lowers the frequency of forced formulation updates and associated re-assessment costs. This is a modest but real demand headwind for stability testing revenue.
Generative AI for marketing creative is creating an indirect compliance demand: brands producing high volumes of AI-generated advertising variants for ROAS optimization on Meta and Google face proportionally higher FTC advertising claim scrutiny surface area. Each AI-generated ad variant that includes a product claim (dermatologist-tested, clinically proven, reef-safe) is technically a claim that requires substantiation under FTC standards. Compliance-aware brands are responding by increasing engagement with third-party claims substantiation consultants to audit their AI-generated creative pipelines, creating a novel and growing service category at the intersection of performance marketing and regulatory affairs.
The cosmetics safety assessment market sits at the intersection of regulatory compliance, ingredient science, and expanding consumer-facing clean beauty claims. Third-party testing bodies, CROs, and specialist dermatological labs generate revenue from services spanning in vitro cytotoxicity and phototoxicity assays to full product stability, SPF validation per ISO 24444:2010, and claims substantiation audits aligned with FTC Green Guides and the EU Green Claims Directive (proposed 2023). The market's base is structurally non-cyclical: once a brand files for market access in a regulated jurisdiction, testing is non-discretionary.
Europe retains the largest regional share, anchored by the long-established EC 1223/2009 framework, which requires a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor for every SKU placed on the EU market. The regulation's prohibition on animal testing for finished products and ingredients — now enforced via the REACH chemical safety dossier interface — has structurally elevated demand for validated in vitro alternatives. BfR (Germany) guidance on endocrine-disrupting ingredients continues to set a de facto supranational standard that even non-EU brands seeking German retail distribution must satisfy.
The United States market is at an inflection. MoCRA, signed into law in December 2022 as part of the Consolidated Appropriations Act, is the first substantive federal cosmetics legislation since the FD&C Act of 1938. It mandates facility registration (deadline: December 2023, with enforcement ramp ongoing), product listing, serious adverse event reporting within 15 business days, and — critically — FDA authority to mandate recalls. Each of these provisions generates discrete demand for third-party documentation, safety dossier preparation, and ongoing post-market surveillance services. The consensus view prices in full-speed MoCRA enforcement from 2025 onward; our contrarian read is that FDA's resource constraints and the sheer volume of newly registered facilities make meaningful enforcement delays through mid-2026 a base-case scenario, not a tail risk. Brands that front-load MoCRA compliance spend in 2025 may find the competitive urgency overstated relative to actual enforcement timelines.
Asia Pacific is reshaping the competitive map. China's NMPA, under the Cosmetics Supervision and Administration Regulation (CSAR) effective May 2021, banned animal testing for most imported general cosmetics by May 2021 and extended that to special-use cosmetics in subsequent guidance, accelerating demand for OECD-validated alternative methods from multinational brands seeking CFDA filing. Japan's PMDA retains a principle-based pre-market notification system, but growing J-Beauty export volumes are driving Japanese contract labs to seek ISO 17025 accreditation for European and North American market access. India's BIS/ISI mandatory certification for cosmetics (BIS CRS scheme, phased rollout 2023–2025) adds a second large emerging-market compliance layer.
The non-animal testing sub-segment deserves particular attention. Reconstructed human epidermis models (e.g., EpiDerm, SkinEthic), 3T3 NRU phototoxicity assays, and Corrositex membrane barrier tests are now OECD TG-validated and EU-mandated defaults. Revenue per assay is structurally higher than legacy LD50 or Draize protocols, and throughput is lower — a favorable mix dynamic for specialist labs. However, AI-driven in silico toxicology platforms (QSAR modeling, read-across automation) are beginning to displace the very lowest-complexity physicochemical hazard screens. This creates a barbell: high-value clinical and dermatological endpoints grow; commodity physicochemical screening compresses on price.
| Year | Market Size (USD Billion) | Period |
|---|---|---|
| 2025 | $3.10B | Base Year |
| 2026 | $3.27B | Forecast |
| 2027 | $3.46B | Forecast |
| 2028 | $3.65B | Forecast |
| 2029 | $3.85B | Forecast |
| 2030 | $4.07B | Forecast |
| 2031 | $4.30B | Forecast |
| 2032 | $4.54B | Forecast |
| 2033 | $4.79B | Forecast |
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Base Year: 2025MoCRA's mandatory facility registration (deadline December 2023) and product listing requirements have brought an estimated 10,000+ facilities under FDA cosmetics oversight for the first time. Adverse event reporting (15-business-day window for serious events) and FDA recall authority create ongoing post-market surveillance obligations that require documented safety assessment programs. Each new requirement generates discrete third-party testing and documentation spend.
The EU's comprehensive ban on animal testing for cosmetics ingredients and finished products, enforced under EC 1223/2009 and reinforced via REACH restriction dossiers, has made validated in vitro alternatives the global default for compliant brands. OECD test guideline updates (TG 439, 442C/D, 492) are continuously expanding the validated in vitro test menu, supporting revenue growth in specialist NAT laboratories.
China's pivot from mandatory animal testing to accepting OECD-validated in vitro alternatives (phased from 2021) for imported general cosmetics is the most significant structural shift in global cosmetics regulation in a decade. Multinational brands seeking CFDA filing must now generate alternative-method safety data packages, creating incremental demand concentrated in Asia Pacific contract labs with NMPA-accepted accreditation.
The FTC's updated Guides for the Use of Environmental Marketing Claims and the EU's proposed Green Claims Directive (2023) are raising the substantiation bar for clean, natural, and sustainable beauty claims. Brands facing potential enforcement action under these frameworks are investing defensively in third-party claims audit and substantiation services, a demand driver that operates independently of product launch cycles.
TikTok Shop and DTC platform expansion has materially increased the population of cosmetics brands requiring safety assessment services; indie and creator-led entrants now account for a growing share of total SKU launches in the US and UK, and these brands overwhelmingly lack in-house regulatory capability, driving outsourcing demand.
Sephora Clean, Ulta Conscious Beauty, and equivalent European retailer standards have made third-party safety and ingredient verification a market-access prerequisite in specialty beauty channels. These retailer-imposed standards update more frequently than regulatory requirements and cover a broader ingredient set, creating a recurring compliance review cycle for listed brands.
AI-driven QSAR modeling and read-across automation platforms (Lhasa Nexus, Leadscope, Toxtree) are enabling brands and formulators to conduct preliminary hazard assessment in-house at near-zero marginal cost. This is compressing per-assay fees for low-complexity physicochemical and basic toxicological screens, creating a structural pricing headwind for commodity testing services. Specialist and high-complexity clinical assays are insulated, but the market's lower margin segments face sustained revenue pressure.
FDA's resource constraints and the volume of newly regulated facilities create a credible scenario in which meaningful enforcement of MoCRA's most commercially impactful provisions (product listing, adverse event reporting, manufacturing standard rules) is delayed 12–18 months beyond current market consensus timing. Brands may defer compliance spend if enforcement signals remain weak, dampening near-term revenue growth for testing providers.
Major CPG conglomerates (Unilever, P&G, L'Oréal, Estée Lauder Companies) operate global in-house safety assessment centers with GLP-compliant laboratories and dedicated safety assessor headcount, limiting the total addressable outsourcing market relative to headline cosmetics industry size. Third-party market share is structurally capped in the large-CPG segment.
Charles River Laboratories reported revenue of USD 4.02B in FY2025 (edgar:CRL-10K-2025), down from USD 4.13B in FY2023 (edgar:CRL-10K-2023), reflecting broad CRO sector demand softness. This pressure is causing diversified testing organizations to prioritize pharma and biotech clients over cosmetics adjacencies, potentially constraining capacity expansion in the cosmetics safety assessment sub-segment during a period of regulatory-driven demand growth.
Brands serving global markets must simultaneously comply with EU EC 1223/2009, US MoCRA, China NMPA CSAR, Japan PMDA, and India BIS requirements that have divergent test method acceptance, dossier formats, and language requirements. While this creates demand for specialist multi-jurisdiction advisory services, it also increases per-brand compliance costs to levels that constrain SME market participants, limiting overall market breadth.
The most clearly sized whitespace in cosmetics safety assessment is multi-jurisdiction compliance-as-a-service for indie and creator-led brands. An estimated 4,000–6,000 new cosmetics brand entrants per year in the US and UK alone now operate primarily through TikTok Shop, Instagram DTC, or Amazon Marketplace (Claritas model). Virtually none have in-house regulatory affairs teams. Full multi-jurisdiction dossier preparation (US MoCRA + EU CPSR + China NMPA alternative-method package) for a 20-SKU brand portfolio is currently a USD 40,000–120,000 engagement when purchased from a major TIC group. A software-enabled compliance platform that productizes dossier preparation at USD 800–1,500 per SKU with integrated lab network access could address a TAM of USD 300–500M annually in the US and EU alone by 2028 (Claritas model). Intertek's Responsible Beauty launch is the first credible move in this direction; the space remains underpenetrated.
Reef-safe and marine ecotoxicology testing represents a specialty capacity gap. Current global laboratory capacity for coral larval toxicity assays and marine invertebrate ecotoxicological studies is concentrated in fewer than 20 facilities worldwide, primarily in the US (Florida, Hawaii) and France (Ifremer). As reef-safe SPF claims migrate from niche positioning to mainstream mass and masstige channel requirements, driven by retailer clean beauty standards and expanding oxybenzone/octinoxate ban legislation, this capacity constraint will become a commercial bottleneck. The total addressable testing market for reef-safe SPF claim substantiation is estimated at USD 180–240M by 2030 (Claritas model), sufficient to support 3–5 dedicated specialty lab investments.
The most underserved geographic opportunity is India, where BIS CRS mandatory certification (phasing in 2023–2025) is creating compliance demand that current laboratory infrastructure cannot absorb. BIS-recognized labs for cosmetics testing are severely limited in number relative to the volume of domestic and imported brands requiring certification; wait times for testing slots are reported at 8–14 weeks. A domestic lab investment or JV between a major TIC group and an Indian testing partner targeting BIS accreditation for cosmetics and personal care products would face minimal competition and strong structural demand tailwinds through at least 2028.
| Region | Market Share | Growth Rate |
|---|---|---|
| Europe | 34% | 4.8% CAGR |
| North America | 29% | 5.8% CAGR |
| Asia Pacific | 27% | 7.1% CAGRFastest |
| Latin America | 6% | 5.4% CAGR |
| Middle East & Africa | 4% | 6.8% CAGR |
Source: Claritas Intelligence — Primary & Secondary Research, 2026.
The cosmetics safety assessment market has a medium-concentration structure: the top five providers (Eurofins Scientific, SGS, Intertek, Bureau Veritas, Charles River) collectively hold an estimated 42–48% of global revenue (Claritas model), with a long tail of regional specialists, dermatological boutiques, and academic contract labs holding the remainder. This structure differs materially from the pharmaceutical CRO market, where top-five concentration exceeds 60%, reflecting cosmetics' greater tolerance for locally accredited regional labs and the absence, until MoCRA, of any US premarket documentation requirement that would reward scale. The competitive moat in this market is not necessarily lab infrastructure, it is accreditation breadth, regulatory affairs expertise, and geographic network. Eurofins' 26-country footprint and SGS's NMPA-accepted China lab are harder to replicate than analytical instrument capacity.
Charles River's declining revenues. USD 4.13B in FY2023 to USD 4.02B in FY2025 (edgar:CRL-10K-2023; edgar:CRL-10K-2025), are a notable signal. The decline reflects pharma biotech spending contraction, not cosmetics-specific weakness, but the CRO sector's capacity consolidation has secondary effects on cosmetics: closure of European in vitro testing sites creates service gaps that pure-play cosmetics testing specialists (Dermatest, Pacific BioLabs) are partially filling. Brands seeking in vitro skin sensitization or ocular irritation data outside the major networks now have more boutique options at competitive price points, which applies marginal downward pressure on the large generalists' cosmetics pricing.
The most consequential competitive dynamic of the forecast period is the emergence of compliance-as-a-service platforms that combine regulatory software (dossier management, adverse event tracking, ingredient notification automation) with access to contracted lab networks. Companies like Registrar Corp (US MoCRA compliance SaaS) and Lextox are blurring the line between testing provider and compliance consultant; if they succeed in building trusted lab network integrations, they could disintermediate the large TIC (testing, inspection, certification) groups from direct brand relationships in the mid-market segment, capturing the advisory margin while outsourcing actual assay work to low-cost labs. This disintermediation risk is real and under-discussed in current competitive analyses.
MoCRA (Modernization of Cosmetics Regulation Act) signed into law as part of the Consolidated Appropriations Act, 2023. First substantive federal cosmetics legislation since 1938; introduces mandatory facility registration, product listing, serious adverse event reporting, and FDA recall authority. Facility registration deadline set for December 29, 2023.
Cosmetics Supervision and Administration Regulation (CSAR) effective May 1, 2021, replacing the 1989 Cosmetics Hygiene Supervision Regulation. CSAR bans animal testing for most imported general cosmetics, introduces the 2021 Inventory of Existing Cosmetic Ingredients in China (IECIC 2021), and establishes a new product category system requiring separate filing pathways for special-use and general cosmetics.
Eurofins completed acquisition of a majority stake in Korean dermatological testing firm K-Beautylab Co., Ltd. (undisclosed value), expanding Eurofins' presence in the South Korean cosmetics market ahead of anticipated MFDS functional cosmetics claim substantiation demand growth. The transaction was Eurofins' fifth Asia Pacific cosmetics-specialist acquisition since 2019.
Intertek launched its Responsible Beauty multi-jurisdiction compliance program, a bundled service covering simultaneous MoCRA (US), EC 1223/2009 (EU), and CSAR (China NMPA) dossier preparation. Priced at a fixed-fee per-SKU structure targeting indie beauty brands with 10–100 SKU portfolios, it was the first major TIC group to productize multi-jurisdiction cosmetics compliance as a single commercial offering.
European Commission published the proposed Green Claims Directive (2023/0085/COD), requiring businesses making voluntary environmental claims on consumer products, including cosmetics, to substantiate claims via third-party verification before making them public. If adopted as proposed, the Directive would come into force in 2026, creating material incremental demand for third-party claims audit services across the EU clean beauty segment.
Charles River announced a USD 50M restructuring and cost-containment program in response to declining pharmaceutical biotech client spending; the program included consolidation of select European in vitro testing sites and reduction of approximately 1,000 positions globally. The restructuring signaled a strategic retreat from capacity-intensive in vitro testing services at a moment of anticipated MoCRA-driven demand growth in cosmetics.
Addressable market by region and by product category. Each cell shows estimated TAM, dominant player, and growth tag.
| Region | Skin Care | Hair Care | Color Cosmetics | Fragrance | Oral Care |
|---|---|---|---|---|---|
| North America | USD 390M Eurofins Scientific Hot | USD 165M Charles River Laboratories Stable | USD 205M Intertek Group Hot | USD 78M Eurofins Scientific Stable | USD 62M SGS SA Stable |
| Europe | USD 352M Eurofins Scientific Hot | USD 142M TÜV SÜD Stable | USD 178M Bureau Veritas Stable | USD 95M SGS SA Stable | USD 71M Eurofins Scientific Stable |
| Asia Pacific | USD 228M SGS SA Hot | USD 188M Intertek Group Hot | USD 215M SGS SA Hot | USD 88M Bureau Veritas Hot | USD 55M Intertek Group Hot |
| Latin America | USD 52M SGS SA Stable | USD 48M Bureau Veritas Stable | USD 44M Intertek Group Stable | USD 22M SGS SA Stable | USD 18M Bureau Veritas Decline |
| Middle East & Africa | USD 32M Bureau Veritas Hot | USD 46M SGS SA Hot | USD 40M Intertek Group Hot | USD 27M SGS SA Hot | USD 11M Bureau Veritas Stable |
MoCRA requires every cosmetics facility to register with FDA (deadline December 2023) and every product to be listed. Brands must report serious adverse events within 15 business days, maintain safety substantiation on file, and comply with any manufacturing standards FDA establishes under the Act. FDA now has recall authority. These requirements apply to both domestic manufacturers and importers. For most small and indie brands, full compliance requires external regulatory consultancy or third-party safety dossier preparation support.
CSAR 2021 phased out the mandatory animal testing requirement for most imported general cosmetics as of May 2021, replacing it with acceptance of OECD-validated in vitro alternative methods. Brands must now submit safety assessment dossiers using recognized alternative methods acceptable to NMPA, along with GMP certification for the manufacturing facility. Special-use cosmetics (hair dye, sunscreen, freckle-lightening) retain additional pre-market registration requirements. The shift has significantly increased demand for in vitro testing services with NMPA-recognized accreditation.
A CPSR is the safety documentation dossier mandated by EU Regulation EC 1223/2009 for every cosmetic product placed on the EU market. It must be signed by a qualified safety assessor (with toxicology or pharmacy degree plus relevant experience) and contains two parts: a product information section (ingredients, specifications, exposure assessment, toxicological profiles) and the safety assessment conclusion. CPSRs must be updated when formulation, packaging, or claims change. Preparation of a CPSR for a complex active-ingredient formulation typically costs EUR 800–3,500 per SKU from a specialist consultant or contract lab.
No single standardized protocol exists for reef-safe claims, which is itself a regulatory risk for brands. At minimum, substantiating reef-safe marketing requires ecotoxicological data demonstrating absence or low toxicity of UV filters and other formulation components to coral larvae, marine invertebrates, and algae. Hawaii Act 104 (effective 2021) bans oxybenzone and octinoxate; compliance with these specific restrictions is documentable. Broader reef-safe claims require aquatic ecotoxicology data that goes beyond standard human safety assessment, typically via specialized environmental testing labs. FTC Green Guides scrutiny of unsubstantiated reef-safe claims is intensifying.
AI-driven QSAR (quantitative structure-activity relationship) modeling and automated read-across platforms allow preliminary hazard assessment for new ingredients based on structural analogy to tested compounds. This compresses early-stage ingredient hazard screening timelines and reduces cost for basic physicochemical assessments. However, regulatory bodies (SCCS, FDA, NMPA) do not yet accept in silico data as a standalone substitute for validated in vitro or human data for final safety conclusions. In silico tools therefore function as pre-screening filters that direct testing investment, not as regulatory replacements for validated assays.
Pharmaceutical-grade safety testing is conducted under GLP (Good Laboratory Practice) regulations (OECD GLP, 21 CFR Part 58) with full study audit trails, archived raw data, and regulatory submission-ready reports. Most cosmetics safety assessments are not conducted under full GLP, though EU CPSR regulations and some retailer standards require GLP-compliant specific assay data. Clinical studies for prestige brand efficacy claims (anti-wrinkle, skin barrier improvement) are often conducted under ICH-adjacent standards, particularly when claims approach drug-like territory. The regulatory gray zone is most pronounced in the US, where FTC advertising claim substantiation standards sometimes de facto require pharmaceutical-grade trial rigor. See our market challenges →
Eurofins Scientific, SGS SA, Intertek Group, Bureau Veritas, and Charles River Laboratories are the five largest providers by geographic reach and service breadth. Eurofins leads in European dermatological and clinical claims substantiation; SGS leads in Asia Pacific, particularly China NMPA-compliant testing; Intertek has the broadest multi-jurisdiction SPF accreditation network. Charles River (Wilmington, MA, founded 1947; edgar:CRL-10K-2025) brings pharmaceutical-grade in vitro toxicology capability. A long tail of regional boutiques. Dermatest (Germany), Pacific BioLabs (US), BioScreen (US), serve specific niche and regional requirements. See our geography analysis →
Our base case projects USD 4.8B by 2033 from USD 3.1B in 2025, at a 5.6% CAGR (Claritas model). The key upside scenario requires full-speed MoCRA enforcement by mid-2025 and rapid EU Green Claims Directive adoption, which could accelerate North American and European demand by 12–18 months. The downside scenario centers on FDA enforcement delays and AI in silico tool adoption compressing entry-level physicochemical screening fees, which could hold market size below USD 4.5B by 2033 under sustained pricing pressure. Specialty clinical services and multi-jurisdiction compliance advisory are the most defensible revenue segments regardless of scenario. See our market size analysis → See our segment analysis →
How this analysis was conducted
Primary Research
Secondary Research
Access detailed analysis, data tables, and strategic recommendations.